Quote:

---

Anyone really think that a potential patient population of 300k or more would really warrant a mere 15 million bucks for a deal for a drug that prevents a severe side effect like oral mucositis?

---

I don't think anyone here thinks that. I said >$15M upfront + phase 3 trial cost . A phase 3 is what? $10M-$50M?

Quote:

---

If we sign a deal with >$15M upfront + a phase 3 cost - definitely.

---

Clarified again for Sox in a later post:

Quote:

---

$15M upfront + phase 3 trial costs in addition to milestones and royalties

---

I thought the consensus here was that this is going to be a royalty company. You minimize upfront to maximize the back end payments.

This is inline with what some other investors more knowledgeable than myself think. Here's BioHedge's take:

https://investorshub.advfn.com/boards/read_ms...=138082418

A deal like that would send the stock well above $2. A 200%+ gain over night.

Regardless, this whole conjecture was a response to NotRichYet2's question about whether 2018 is the year IPIX. I believe we will hit both of the targets I proposed and if we do, IPIX will hit new highs by the end of the year.

Go IPIX!